BACKGROUND: Mild cognitive impairment is increasingly recognized as an important public health problem associated with increased risk of developing dementia. Annual conversion rates, however, vary across different studies with clinic samples showing higher rates of conversion than community-based samples. OBJECTIVES: To establish whether the rates of conversion from mild cognitive impairment to dementia differed according to recruitment source and, if so, to investigate factors that might explain this discrepancy. DESIGN: Rates and predictors of conversion were examined in a prospective longitudinal study at a single center. SETTING: Among the participants, 46% were recruited from a clinical setting and 54% were recruited directly through community outreach. PARTICIPANTS: One hundred eleven individuals with mild cognitive impairment were followed up longitudinally for an average of 2.4 years (range, 0.5-4.0 years). MAIN OUTCOME MEASURES: Conversion from mild cognitive impairment to dementia. RESULTS: During the follow-up period, 28 individuals progressed to dementia with a mean (SD) time to conversion of 2.19 (0.72) years. The clinic sample had an annual conversion rate of 13%, whereas the community sample had an annual conversion rate of 3%. In a Cox proportional hazards model, clinic recruitment source alone was associated with an increased hazard of incident dementia (hazard ratio = 3.50; 95% confidence interval, 1.31-9.18; P = .01). When other variables were added to the model, only baseline functional impairment as measured by the Clinical Dementia Rating Scale (and no demographic, cognitive, or neuroimaging variables or mild cognitive impairment subtype) accounted for the differences in conversion rates across the 2 cohorts. CONCLUSIONS: These findings add to the growing literature to suggest that the degree of functional impairment at baseline is an important predictor of conversion to dementia and may help explain differences in findings between epidemiological and clinic-based studies.
BACKGROUND: Mild cognitive impairment is increasingly recognized as an important public health problem associated with increased risk of developing dementia. Annual conversion rates, however, vary across different studies with clinic samples showing higher rates of conversion than community-based samples. OBJECTIVES: To establish whether the rates of conversion from mild cognitive impairment to dementia differed according to recruitment source and, if so, to investigate factors that might explain this discrepancy. DESIGN: Rates and predictors of conversion were examined in a prospective longitudinal study at a single center. SETTING: Among the participants, 46% were recruited from a clinical setting and 54% were recruited directly through community outreach. PARTICIPANTS: One hundred eleven individuals with mild cognitive impairment were followed up longitudinally for an average of 2.4 years (range, 0.5-4.0 years). MAIN OUTCOME MEASURES: Conversion from mild cognitive impairment to dementia. RESULTS: During the follow-up period, 28 individuals progressed to dementia with a mean (SD) time to conversion of 2.19 (0.72) years. The clinic sample had an annual conversion rate of 13%, whereas the community sample had an annual conversion rate of 3%. In a Cox proportional hazards model, clinic recruitment source alone was associated with an increased hazard of incident dementia (hazard ratio = 3.50; 95% confidence interval, 1.31-9.18; P = .01). When other variables were added to the model, only baseline functional impairment as measured by the ClinicalDementia Rating Scale (and no demographic, cognitive, or neuroimaging variables or mild cognitive impairment subtype) accounted for the differences in conversion rates across the 2 cohorts. CONCLUSIONS: These findings add to the growing literature to suggest that the degree of functional impairment at baseline is an important predictor of conversion to dementia and may help explain differences in findings between epidemiological and clinic-based studies.
Authors: Matthias H Tabert; Jennifer J Manly; Xinhua Liu; Gregory H Pelton; Sara Rosenblum; Marni Jacobs; Diana Zamora; Madeleine Goodkind; Karen Bell; Yaakov Stern; D P Devanand Journal: Arch Gen Psychiatry Date: 2006-08
Authors: K Pérès; V Chrysostome; C Fabrigoule; J M Orgogozo; J F Dartigues; P Barberger-Gateau Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: B J Gurland; D E Wilder; R Lantigua; Y Stern; J Chen; E H Killeffer; R Mayeux Journal: Int J Geriatr Psychiatry Date: 1999-06 Impact factor: 3.485
Authors: Sarah T Farias; Dan Mungas; Bruce R Reed; Danielle Harvey; Deborah Cahn-Weiner; Charles Decarli Journal: Alzheimer Dis Assoc Disord Date: 2006 Oct-Dec Impact factor: 2.703
Authors: Rhoda Au; Joseph M Massaro; Philip A Wolf; Megan E Young; Alexa Beiser; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli Journal: Arch Neurol Date: 2006-02
Authors: Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco Journal: Am J Neurodegener Dis Date: 2012-11-18
Authors: Mary Ganguli; Ching-Wen Lee; Beth E Snitz; Tiffany F Hughes; Eric M McDade; Chung-Chou H Chang Journal: Alzheimer Dis Assoc Disord Date: 2014 Apr-Jun Impact factor: 2.703
Authors: Tanis J Ferman; Glenn E Smith; Kejal Kantarci; Bradley F Boeve; V Shane Pankratz; Dennis W Dickson; Neill R Graff-Radford; Zbigniew Wszolek; Jay Van Gerpen; Ryan Uitti; Otto Pedraza; Melissa E Murray; Jeremiah Aakre; Joseph Parisi; David S Knopman; Ronald C Petersen Journal: Neurology Date: 2013-11-08 Impact factor: 9.910
Authors: Ronald C Petersen; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; Glenn E Smith; Clifford R Jack Journal: Arch Neurol Date: 2009-12